YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Tributary Capital Management released its second-quarter 2026 investor letter for "Multi Cap Core Equity Strategy". You can download a copy of the letter here. The Tributary Multi Cap Core's equity allocation underperformed in Q2, returnin…
GLOUCESTER, England, September 23, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Gree…
GHO Capital Vivid brings over 30 years of operational and financial leadership in healthcare and life sciences, being a founder of LivaNova PLC, led OPEN Health as Interim Group CEO, and held senior roles at GlaxoSmithKline, Allergan, and…
GLOUCESTER, England, September 03, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City: Mor…
NeuroPace, Inc. NPCE has hit a regulatory delay in its bid to expand the RNS System into idiopathic generalized epilepsy, or IGE. The FDA's July 2026 response pushes out a potential growth catalyst beyond the company's established focal ep…
NeuroPace, Inc. NPCE is showing better operating momentum as RNS System adoption expands and losses narrow. Second-quarter results supported the growth case, while a broader commercial reach and new technology tools could deepen utilizatio…
NeuroPace, Inc. NPCE shares have declined 12.7% in the past three months even as the company's core responsive neurostimulation, or RNS, franchise has continued to strengthen. The pullback leaves investors weighing improving focal-epilepsy…
LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance,…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guid…
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Briana Gotlin Chief Executive Officer and member of the Board of Directors - Vladimir Makatsaria Chief Inn…
LivaNova LIVN reported adjusted earnings per share (EPS) of $1.26 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 16.7%. GAAP EPS for the quarter was $1.93 compared with 50 cents in th…
LivaNova PLC Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Achiev…
This article first appeared on GuruFocus. Revenue: $391 million in Q2 2026, an increase of 9.8% on a constant currency basis versus the prior year. Cardiopulmonary Revenue: $222 million in the quarter, up 10% year-over-year, led by strengt…
Inspire Medical Systems, Inc. INSP raised its 2026 outlook after second-quarter results exceeded expectations. Better cost control, a richer mix of Inspire V implants and stronger cash generation helped offset a continued decline in U.S. p…
Key Points Interested in LivaNova PLC? Here are five stocks we like better. Record Q2 performance: Revenue rose 9.8% year over year on a constant-currency basis to $391 million, while adjusted EPS increased to $1.26 from $1.05, supported b…
For the quarter ended June 2026, LivaNova (LIVN) reported revenue of $390.6 million, up 10.8% over the same period last year. EPS came in at $1.26, compared to $1.05 in the year-ago quarter. The reported revenue compares to the Zacks Conse…
A strong stock as of late has been LivaNova (LIVN). Shares have been marching higher, with the stock up 2.1% over the past month. The stock hit a new 52-week high of $85.76 in the previous session. LivaNova has gained 38.7% since the start…
Graph showing growth ©Adobe Stock Images LivaNova (NASDAQ:LIVN) reported second-quarter results that surpassed Wall Street expectations, prompting the medical technology company to raise its earnings and revenue guidance for the full year.…
LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items. This…
– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8% – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) – Entered into a long-term agreement with Thermo F…
Over the past several months, generative AI (GenAI) has evolved from experimental to practical applications in the Medical Instruments industry. Companies are leveraging the technology to generate synthetic medical images, simulate disease…
A strong stock as of late has been LivaNova (LIVN). Shares have been marching higher, with the stock up 12.3% over the past month. The stock hit a new 52-week high of $85.27 in the previous session. LivaNova has gained 36.6% since the star…
LONDON, June 24, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. E…
LivaNova LIVN recently announced new data from the PolySync substudy showing that its PolySync programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate from 65% to 84.5% in patients with moderate-to-severe Ob…
– Presentation at SLEEP 2026 illustrates ability to convert non-responders into responders using personalized programming LONDON, June 16, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, tod…
Cytokinetics (NASDAQ:CYTK) is one of the most promising mid-cap stocks to buy according to analysts. On June 1, Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova stock reacts to recent performance metrics LivaNova (LIVN)…
LONDON, June 11, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors after its Annual General Meeting of shar…
LONDON, June 05, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s g…
NeuroPace, Inc. NPCE is moving through a clean strategic reset in 2026. The company is exiting the DIXI Medical distribution business and leaning fully into its core responsive neurostimulation franchise, where reimbursement and pricing ac…
NeuroPace, Inc. NPCE is tightening its focus around one thing: the RNS System, a closed-loop implant built for drug-resistant epilepsy. The setup is designed to generate recurring procedure-driven revenues, supported by reimbursement tailw…
NeuroPace, Inc. NPCE is tightening its focus on the core RNS franchise as it exits the DIXI distribution and leans into workflow upgrades designed to expand clinician capacity. The company is positioning software, not just hardware, as the…
LONDON, May 21, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succee…
LONDON, May 19, 2026--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Ma…
LivaNova (LIVN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A c…
LivaNova PLC previously reported that first-quarter 2026 sales rose to US$362.26 million from US$316.86 million a year earlier, with net income improving to US$22.29 million from a very large net loss and basic earnings per share from cont…